Cancer Therapeutics: Technology, Discovery, and Targeted Delivery Program

癌症治疗：技术、发现和靶向治疗项目

基本信息

批准号：
10230666
负责人：
CHERYL LYNN WILLMAN
金额：
$ 0.68万
依托单位：
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-09-26 至 2021-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10230666
关键词：
Advisory Committees Aerosols Animal Model Antibodies Antineoplastic Agents Bacteriophages Biological Biological Assay Biological Models Biology Biomedical Engineering Biotechnology Blood Vessels Cancer Biology Cancer Center Cancer Center Support Grant Cancer Diagnostics Cell Surface Receptors Cells Clinical Clinical Investigator Clinical Trials Clinical Trials Network Collaborations Coupled Critiques Diagnostic Imaging Direct Costs Doctor of Philosophy Drug Delivery Systems Early Intervention Engineering Evaluation Faculty Flow Cytometry Foundations Funding G-Protein-Coupled Receptors Goals Grant Human Hydrogels Image Industry Informatics Infrastructure Integrins Intellectual Property Intervention Intervention Studies Intervention Trial Investigation Isotopes Laboratories Lead Leukocytes Libraries Ligands Malignant Neoplasms Mathematics Methods Mission NCI Center for Cancer Research Nanotechnology Neoplasm Circulating Cells New Mexico Normal Cell Normal tissue morphology Oral Pathologic Pathway interactions Peer Review Peptide antibodies Peptides Phage Display Pharmaceutical Preparations Pharmacologic Substance Pharmacy facility Phase Phase I Clinical Trials Phosphorylation Physicians Population Prediction of Response to Therapy Publications Publishing Research Research Institute Research Personnel Route Scientist Silicon Dioxide Talents Technology Therapeutic Therapeutic Agents Therapeutic Intervention Therapeutic Uses Tissues Translating Translations Tumor Tissue United States National Institutes of Health Universities Virus-like particle Work base cancer cell cancer clinical trial cancer imaging cheminformatics clinical application clinical translation college combinatorial commercialization design drug discovery experience high throughput screening imaging agent in vitro Model in vivo innovation investigator-initiated trial mathematical methods mathematical model medical schools member molecular imaging multidisciplinary nanoGold nanofabrication nanoparticle nanoscience novel pre-clinical programs receptor recruit respiratory response small molecule small molecule inhibitor targeted delivery targeted treatment translational pipeline translational scientist working group

项目摘要

CANCER THERAPEUTICS: TECHNOLOGY, DISCOVERY & TARGETED DELIVERY (CT) RESEARCH PROGRAM ABSTRACT The Cancer Therapeutics: Technology, Discovery and Targeted Delivery (CT) Research Program, led by Larry A. Sklar, PhD and Renata Pasqualini, PhD, consists of a multidisciplinary team of 43 (27 full and 16 associate members) of basic, translational and clinical investigators assembled from 5 Departments in the UNM School of Medicine, 2 in the UNM College of Engineering, the UNM College of Pharmacy, New Mexico State University, and our UNM Cancer Center (UNMCC) consortium partners: Lovelace Respiratory Research Institute (LRRI) and Sandia (SNL) and Los Alamos National (LANL) Laboratories. CT is a new UNMCC Research Program, developed through rigorous program planning and evaluation in response to the prior 2010 NCI CCSG critique and guidance from the External Advisory Committee (EAC). Building from its origins in the Cancer Biotechnology component of the former Cancer Biology & Biotechnology Program, CT has retained and acquired scientific expertise in small molecule discovery and drug repurposing, combinatorial targeting of peptide and antibody phage display libraries, nanoparticle and virus-like particle (VLP)-based drug delivery, as well as imaging and isotopes. During the prior funding period (from 1/1/10 to 9/1/2014), CT program members published 336 original peer-reviewed articles and reviews (37% intra-programmatic and 24% inter-programmatic) and participated in 6 investigator-initiated trials. As of 9/1/14, CT funding is $16,076,676 in annual direct costs, of which $14,196,182 is peer-reviewed direct funding and $3,105,330 is from the NCI. Dr. Sklar is an expert in leukocyte biology and drug discovery and/or repurposing while Dr. Pasqualini is an expert in vascular targeting whose pivotal work in vivo with phage display has led to extensive pre-clinical and clinical applications; both leaders are experienced in translation and commercialization. CT has contributed to the bulk of UNMCC intellectual property as well as 10 biotechnology or pharmaceutical start-up companies. The Program benefits from the technological expertise in partnerships among the UNMCC, LRRI, SNL and LANL. Through the strategic recruitment of new talented faculty and infrastructure reorganization, the CT translational pipeline is expanding through: i) small molecule discovery and drug repurposing, flow cytometry technology and cheminformatics; ii) combinatorial targeting through selection of peptide and antibody phage display libraries; iii) targeted ligand-directed delivery coupled to material nanofabrication, predictive mathematical methodology, and molecular imaging; and iv) early translation into clinical application. Noted multidisciplinary, multi-investigator programmatic grants held by CT members include large NIH, NCI and DOD funds supporting translational investigations and clinical interventions. Recent physician-scientist and clinical investigator recruits will lead the current and planned portfolio of early investigator-initiated clinical trials. CT's overall goal is to discover, develop and translate innovative platform technologies into cancer diagnostic and therapeutic applications by using bioengineering, biotechnology, nanotechnology, phage display, mathematics and informatics as the basis for early interventional clinical trials.

癌症治疗：技术、发现和靶向治疗 (CT) 研究计划抽象的癌症治疗：技术、发现和靶向递送 (CT) 研究项目，由 Larry 领导 A. Sklar 博士和 Renata Pasqualini 博士由 43 名多学科团队组成（27 名全职和 16 名助理）成员）由来自新墨西哥大学医学院 5 个系的基础、转化和临床研究人员组成医学，2 新墨西哥州立大学工程学院、新墨西哥州立大学药学院、新墨西哥州立大学以及我们的新墨西哥大学癌症中心 (UNMCC) 联盟合作伙伴：洛夫莱斯呼吸研究所 (LRRI) 桑迪亚 (SNL) 和洛斯阿拉莫斯国家 (LANL) 实验室。 CT是一个新的UNMCC研究项目，经过严格的计划规划和评估而制定，以回应 2010 年 NCI CCSG 之前的批评以及外部咨询委员会 (EAC) 的指导。源于癌症生物技术作为前癌症生物学和生物技术计划的组成部分，CT 保留并获得了科学小分子发现和药物再利用、肽和抗体组合靶向方面的专业知识噬菌体展示库、基于纳米颗粒和病毒样颗粒 (VLP) 的药物递送以及成像和同位素。在上一资助期间（从 1/1/10 到 9/1/2014），CT 项目成员发表了 336 篇原创文章同行评审的文章和评论（37% 属于计划内，24% 属于计划间）并参与了 6 研究者发起的试验。截至 2014 年 9 月 1 日，CT 资金的年度直接成本为 16,076,676 美元，其中 14,196,182 美元是经过同行评审的直接资助，其中 3,105,330 美元来自 NCI。 Sklar 博士是白细胞生物学方面的专家药物发现和/或重新利用，而 Pasqualini 博士是血管靶向领域的专家，其关键工作是噬菌体展示的体内技术已获得广泛的临床前和临床应用；两位领导人都经验丰富在翻译和商业化方面。 CT 为 UNMCC 的大部分知识产权做出了贡献 10家生物技术或制药初创公司。该计划受益于技术专长 UNMCC、LRRI、SNL 和 LANL 之间建立伙伴关系。通过战略性招聘新人才师资和基础设施重组，CT 转化管道正在通过以下方式扩展： i) 小分子发现和药物再利用、流式细胞术技术和化学信息学； ii) 组合目标通过选择肽和抗体噬菌体展示文库； iii) 靶向配体定向递送偶联材料纳米制造、预测数学方法和分子成像； iv) 早期翻译进入临床应用。注意到 CT 成员持有的多学科、多研究者计划资助包括支持转化研究和临床干预的大型 NIH、NCI 和 DOD 基金。最近的新招募的医师科学家和临床研究人员将领导当前和计划的早期投资组合研究者发起的临床试验。 CT的总体目标是发现、开发和转化创新平台通过使用生物工程、生物技术、纳米技术、噬菌体展示、数学和信息学作为早期介入临床试验的基础。